A collection of seven articles in Best Practice & Research Clinical Obstetrics & Gynaecology, led by Visiting Editor Anita Makins, brings together global expertise on post-pregnancy contraception - an area critical to improving maternal and newborn health outcomes worldwide.
The INTERBIO-21st study has identified that a pattern of fats identified in the blood of mothers early in pregnancy is associated with reduced rates of brain growth in the baby, and developmental delays in the children once they reach 2 years of age.
Researchers from the University of Oxford and the Francis Crick Institute, in collaboration with international partners, have made major advances in understanding how mutations in a single non-coding gene contribute to neurodevelopmental disorders affecting thousands of people worldwide.
A new Anti-Racist Medicine textbook explores racism\u2019s impact on healthcare, research and education, and offers guidance for delivering more equitable care.
Congratulations to Dr Onima Chowdhury, who has been awarded a clinical trial grant by Cancer Research UK to improve treatment of Myelodysplastic Syndromes.
Professor Prasanna Sooriakumaran, from the University of Oxford\u2019s Nuffield Department of Surgical Sciences (NDS), has been awarded a \u00a33 million grant from the Department of Health and Social Care to lead a major new clinical trial that could transform the global treatment of early, lethal prostate cancer.
The authors of a new paper explain how a new methodology helped them better understand student wellbeing at Oxford and what more could be done to support mental health.
Current World Health Organization (WHO) guidelines typically recommend 2\u20137 days of abstinence before taking semen samples or assisted reproduction. However, a new study published today and led by Oxford University researchers suggests that regular ejaculation \u2013 whether through sexual activity or masturbation \u2013 results in higher quality sperm, with less DNA damage.
Nuffield Department of Primary Care Health Sciences (NDPCHS) hosted its first Annual Showcase and Lecture at the Oxford Union, bringing together leading voices in primary care research, education and global health innovation, including a keynote address by Lord Vallance.
A new study, co-led by Professor Arjune Sen and supported by Nuffield Department of Clinical Neurosciences, aims to improve understanding of the risk factors, care pathways and broader health and social impacts of epilepsy in Nepal.
Oxford University spinout Dark Blue Therapeutics has been acquired by global biotechnology company Amgen in a deal worth up to US$840 million, marking a major milestone for Oxford-led cancer research and innovation. The deal reflects years of collaborative, multidisciplinary work across the University and its partners to translate fundamental research into promising new medicines.
Heavy social media use appears to be contributing to the drop in wellbeing among young people in English-speaking countries and Western Europe, especially among girls, according to findings published today (19 March) in the 2026 edition of the World Happiness Report.
A new research centre backed with \u00a311 million from GSK will build open-source digital twins of organs for in-silico research to advance disease understanding and speed up development of new drugs.
New investment at Oxford\u2019s Nuffield Department of Primary Care Health Sciences will support academic leadership, research capacity and training in Tunisia
Two international studies, a clinical trial led by the University of Oxford and University of Utrecht, and a qualitative study led by the University of Oxford and University of Antwerp, report that point-of-care diagnostic testing, when used alone is unlikely to reduce antibiotic prescribing for respiratory tract infections in primary care. The findings indicate that testing must be embedded within broader antimicrobial stewardship strategies to be effective.
The University of Oxford and Serum Institute of India Pvt. Ltd. (SII), a Cyrus Poonawalla Group company and the world\u2019s largest vaccine manufacturer, have signed an Intellectual Property license agreement to advance the development and manufacture of the ChAdOx1 NipahB vaccine candidate.
![\"Woman](\"https://www.medsci.ox.ac.uk/news/global-series-highlights-innovations-and-impact-in-post-pregnancy-contraception/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n